Why Venture
Philantrophy?

We believe the best chance at success in bringing cures and treatments to inheritable blood disorders community is to invest in promising therapies and technologies and help guide them through development. As flexible partners that offer significant added value to portfolio companies and private capital partners, P2C will close the funding-gap for early-stage biotech companies.

With a venture philanthropy model, P2C can leverage our philanthropic capital, expertise and resources to “de-risk” investments for private capital partners and build a portfolio of investments with the potential to make transformational impact across inheritable blood disorders.

P2C’s targeted investment strategy is focused on guiding and advancing portfolio companies to bring them closer to clinical development. While there is risk associated with early-stage investments, there is also the opportunity to build a pathway to cures and improve the quality of life of more than 20 million patients living with inherited blood disorders worldwide. As a high-impact philanthropic vehicle, all returns from the Fund’s investments will be recycled back into furthering P2C’s mission.

Our Investment Approach

P2C takes a targeted and selective approach to investment opportunities, partnering with companies that meet four primary criteria: Innovation, Mission Impact, Partnerships, and Financial Return Potential.

Innovation: P2C will invest in new therapeutic approaches at any stage of the R&D continuum from discovery through the clinic if they show potential to significantly improve a patient’s quality of life.

Mission Impact: P2C will focus on investing in therapies and technologies that align with our mission to accelerate transformational change for people living with inheritable blood disorders.

Partnerships: P2C will partner with venture capital, biotech, and pharma companies, among others, to close the funding-gap for early-stage pipeline development, charting a new pathway for cures and innovative therapies.

Financial Return Potential: P2C will only consider partnering with and investing in companies that are financially viable and offer the potential of a return on investment. Having an investible business model is a key criterion that must be met to bring in outside capital and fuel future opportunities for the Fund to create transformational change.

What We Invest In

First-in-class therapeutics or novel therapeutic mechanisms with curative potential for inheritable blood disorders

Novel, precision diagnostics that have the potential to transform clinical practice by enabling earlier or more accurate diagnoses and closing health equity gaps

Novel technologies that have the potential to revolutionize treatment of inheritable blood disorders or to disrupt the conventional care delivery model in ways that significantly close equity gaps

How We Invest

To ensure the long-term health of the Fund and the realization of its mission, P2C adopts industry standard investment considerations generally accepted and used by venture capital.

P2C makes equity investments traditionally but is open to a wide array of investment structures

All investment opportunities are strictly confidential. Opportunities will be reviewed internally to ensure mission focus and strategic alignment

P2C adopts and abides by the general venture capital industry standards when conducting the diligence process